Enabling technology plays an important role in the life sciences sector in drug discovery. These are the research tools that make the process more efficient and easier for new drugs to reach the market. The Ontario/Québec corridor, second only to Boston and Southern California in terms of research strength in life sciences, is key to Ontario’s ability to compete globally on this front.
Now, two Ontario Centres of Excellence (OCE)-backed projects are the first to be approved under an Ontario-Québec life sciences research partnership aimed at developing enabling technologies for the drug discovery process.
The first, a partnership between McMaster University, Sunnybrook Research Institute, Spectral Applied Research
in Richmond Hill and the National Optics Institute
in Québec City is developing an instrument add-on device to improve efficiency in drug screening processes.
And the second, a partnership between Toronto’s InDanio Biosciences
and McGill University in Montreal is advancing development of a new drug discovery platform for cancer and metabolic disease therapies.
The two OCE projects were among eight under consideration.
"OCE is pleased that our projects have been recognized as important to this partnership," says Dr. Tom Corr, President and CEO of OCE. "Through our academic and industry networks as well as our expertise in mentoring, we have been able to support candidates that will further develop their ideas to enable growth and innovation across Ontario and into Québec."
The partnership was the first initiative out of the “Ontario-Québec Life Sciences Corridor,” announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.